The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Secondary Progressive Multiple Sclerosis: New Insights
Open accessAbstract
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools that, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationPathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Self-citationKappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationBenedict, R. H., DeLuca, J., Phillips, G., LaRocca, N., Hudson, L. D., Rudick, R., & Multiple Sclerosis Outcome Assessments Consortium (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690821 · Cited by 839
Frischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Self-citationPathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
Self-citationKappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Self-citationProgressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Cognition in multiple sclerosis: State of the field and priorities for the future
Sumowski, J. F., Benedict, R., Enzinger, C., Filippi, M., Geurts, J. J., Hamalainen, P., Hulst, H., Inglese, M., Leavitt, V. M., Rocca, M. A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004977 · Cited by 519
Cited by
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment
Haki, M., AL-Biati, H. A., Al-Tameemi, Z. S., Ali, I. S., & Al-hussaniy, H. A. (2024) · Medicine · doi:10.1097/md.0000000000037297 · Cited by 274
Motor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm
Lubrich, C., Giesler, P., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911342 · Cited by 77
Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS
Jhelum, P., Zandee, S., Ryan, F., Zarruk, J. G., Michalke, B., Venkataramani, V., Curran, L., Klement, W., Prat, A., & David, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01617-7 · Cited by 49
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Metadata
- Authors
- Cree, B. A. C., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A., Murphy, N., & Lassmann, H.
- Venue
- Neurology
- Published
- 2021-08-24
- Volume
- 97
- Issue
- 8
- Pages
- 378-388
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3165109500
- Cited by
- 260
- References
- 51
- FWCI
- 23.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary Progressive Multiple Sclerosis: New Insights. https://app.cochat.ai/papers/10.1212/wnl.0000000000012323
- The paper
- Cree, B. A. C., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A., Murphy, N., & Lassmann, H. (2021). Secondary Progressive Multiple Sclerosis: New Insights. Neurology. https://doi.org/10.1212/wnl.0000000000012323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.